LUTRIS PHARMA
Lutris Pharma develops drugs to improve anti-cancer therapy effectiveness. The company develops the topical B-Raf inhibitor LUT014, a proprietary small molecule that allows administration of epidermal growth factor receptor (EGFR) inhibitors to patients without the interruptions caused by typical cutaneous side effects. Lutris Pharma was established in 2015 and is based in Tel Aviv-yafo, Israel.
LUTRIS PHARMA
Industry:
Biotechnology First Aid Health Care Wellness
Founded:
2015-12-01
Address:
Tel Aviv-yafo, Tel Aviv, Israel
Country:
Israel
Website Url:
http://www.lutris-pharma.com
Total Employee:
1+
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Global Site Tag Yoast WordPress SEO Plugin
Current Employees Featured
Noa Shelach Founder & CEO @ Lutris Pharma
Founder & CEO
Founder
Official Site Inspections
http://www.lutris-pharma.com Semrush global rank: 6.13 M Semrush visits lastest month: 1.32 K
- Host name: box5760.bluehost.com
- IP address: 162.241.253.30
- Location: Provo United States
- Latitude: 40.2342
- Longitude: -111.6442
- Metro Code: 770
- Timezone: America/Denver
- Postal: 84606
More informations about "Lutris Pharma"
Home - Lutris Pharma
Lutris Pharma is a clinical stage biopharmaceutical company established with a vision to improve anti cancer therapy effectiveness as well as the quality of life for patients who are being …See details»
Lutris Pharma - Crunchbase Company Profile & Funding
Lutris Pharma develops drugs to improve anti-cancer therapy effectiveness. The company develops the topical B-Raf inhibitor LUT014, a proprietary small molecule that allows …See details»
Investors - Lutris Pharma
Lutris-Pharma is established by industry experts and leaders: Dr. Antoni Ribas, Pontifax and Arkin Holdings. Pontifax is a healthcare dedicated venture capital firm with over $600 million under management.See details»
Management Team - Lutris Pharma
Prior to Lutris-Pharma, Dr. Shelach held CEO positions in leading private and public biopharmaceutical companies: NextGen Healthcare, Integra Holdings, Campus Bio (Held by: …See details»
Lutris Pharma - PitchBook
Information on valuation, funding, cap tables, investors, and executives for Lutris Pharma. Use the PitchBook Platform to explore the full profile.See details»
Lutris Pharma - LinkedIn
Lutris Pharma is a clinical stage biopharmaceutical company focused on improving anti-cancer therapy effectiveness and quality of life for patients who are being treated with EGFR (Epidermal...See details»
Lutris Pharma Receives FDA Orphan Drug Designation …
Feb 28, 2024 · Lutris Pharma is a clinical stage biopharmaceutical company focused on improving anti-cancer therapy effectiveness and quality of life for patients who are being treated with EGFR (Epidermal...See details»
Lutris Pharma - VentureRadar
Lutris-Pharma was established with a vision of improving anti-cancer therapy effectiveness as well as the quality of life for patients that are treated with EGFR (Epidermal Growth Factor …See details»
Lutris Pharma Receives FDA Orphan Drug Designation for LUT014 …
Feb 28, 2024 · Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects, today announced that the U.S. …See details»
Board of Directors - Lutris Pharma
Today the company owns a healthcare portfolio of $1 billion through four investment arms, with holdings in some 20 Israeli companies developing pharmaceutical drugs and equipment. Previously Mr. Arkin headed Agis, …See details»
Lutris Pharma Appoints Company Founder, Antoni Ribas, M.D., …
TEL AVIV, Israel, May 10, 2022 /PRNewswire/ -- Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose …See details»
Lutris Pharma Ltd. (Lutris Pharma Ltd.) - 药物管线_专利_临床试验_ …
About Lutris Pharma Lutris Pharma is a clinical stage biopharmaceutical company focused on improving anti-cancer therapy effectiveness and quality of life for patients who are being …See details»
Lutris-Pharma - Products, Competitors, Financials, Employees ...
Lutris-Pharma is a clinical stage biopharmaceutical company that operates in the healthcare sector, focusing on improving the effectiveness of anti-cancer therapies. Use the CB Insights …See details»
Lutris Pharma Appoints Life Science Executive, Jack Weinstein, as ...
Jun 29, 2021 · Lutris Pharma is a clinical stage biopharmaceutical company focused on improving anti-cancer therapy effectiveness and quality of life for patients who are being treated with …See details»
Press Releases - Lutris Pharma
Oct 24, 2022 · Lutris Pharma Reports Positive Top-Line Results From the Open Label Part 1 and Double Blinded Part 2 of Its Phase 1/2 Trial of LUT014 to Treat Radiation Dermatitis in …See details»
Lutris Pharma Appoints Company Founder, Antoni Ribas, M.D., …
May 10, 2022 · Lutris Pharma is a clinical stage biopharmaceutical company focused on improving anti-cancer therapy effectiveness and quality of life for patients who are being …See details»
Publications - Lutris Pharma
A topical BRAF inhibitor (LUT-014) for treatment of radiodermatitis among women with breast cancerSee details»
Lutris Pharma Completes Enrollment in Phase 2 Trial of
Oct 15, 2024 · Lutris Pharma is a clinical stage biopharmaceutical company focused on improving anti-cancer therapy effectiveness and quality of life for patients who are being treated with …See details»
Lutris Pharma's Founder and Chairman of the Board Receives $5.0 …
TEL AVIV, Israel, Oct. 24, 2022 /PRNewswire/ -- Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose …See details»
Lutris Pharma Expands Intellectual Property Portfolio Surrounding …
Dec 8, 2021 · Lutris Pharma's lead asset, LUT014, a topical B-Raf Inhibitor, is a proprietary, first-in-class, small molecule currently in a phase 2 clinical trial in metastatic colorectal cancer …See details»